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Abstract
Background Statins are the mainstay hypercholesterolemia
treatment and reduce the risk of cardiovascular events in
patients. However, statin therapy is often interrupted in
patients experiencing musculoskeletal pain or myopathy,
which are common in this patient group. Currently, the
standard tests for diagnosing statin myopathies are difficult
to interpret. A pharmacogenomics (PGx) test to diagnose
statin-induced myopathy would be highly desirable.
Methods We developed a Markov state model to assess the
cost-effectiveness of a hypothetical PGx test, which aims to
identify statin-induced myopathy in high-risk, secondary
prevention cardiovascular patients. The alternative strategy
hypothesized is that physicians or patients interrupt the
statin therapy in the presence of musculoskeletal pain. Our
model includes health states specific to the PGx test out-
come which assesses the impact of test errors.
Results Assuming a perfect test, the results indicate that
the PGx test strategy dominates when the test costs less
than CAN$356, when the strategy is cost neutral. These
results are robust to deterministic and probabilistic sensi-
tivity analyses.
Conclusion Our base-case results show that a PGx test for
statin-induced myopathy in a high-risk, secondary pre-
vention of a cardiovascular event population would be a
dominant solution for a test cost of CAN$356 or less.
Furthermore, the modelling of the complete range of
diagnostic test outcomes provide a broader understanding
of the economic value of the pharmacogenomics test.
Key Points for Decision Makers
Physicians and pharmacists often discontinue statin
therapy in patients with musculoskeletal pain. Even
when physicians and pharmacists recommend
alternative strategies to maintain the statin therapy,
patients may decide to not follow their
recommendations. This premature discontinuation
results in many patients being deprived of the drug’s
beneficial cardiovascular prevention.
An accurate pharmacogenomics (PGx) test to
identify musculoskeletal pain resulting from statin
therapy is highly desirable. It would fulfill a need for
physicians and pharmacists, but it may also be more
useful as tool to convince patients to adhere and
persist on statin therapy.
The results of our simulation show that a PGx test to
identify statin-induced myopathy is dominant with a
test cost of less than CAN$356. Assuming a public
payer willingness to pay of CAN$1000, the PGx test
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1 Introduction
In Canada, 13.7 million individuals suffer from elevated
cholesterol levels (i.e. hypercholesterolemia) [1]. Statins
are the mainstay hypercholesterolemia treatment; reducing
the risk of a cardiovascular event (CVE) by as much as
25–35% [2]. It is estimated that 3–4 million Canadians are
currently prescribed a statin to reduce their cholesterol
level [3]. One associated adverse effect of statin therapy is
myopathy, a form of musculoskeletal pain, that may lead to
the interruption of treatment.
Musculoskeletal pain consists of common symptoms,
with a range of origins, from strenuous physical activity to
statin-induced myopathy. Currently, statin-induced
myopathy is diagnosed using creatine kinase (CK) tests,
which have limited diagnostic capacity due to poor internal
validity. For instance, musculoskeletal pain detected with
CK values could have resulted from heavy exercise rather
than statin therapy [4]. In more serious cases, rhabdomy-
olysis, the extreme condition in which muscle breaks
down, potentially leading to severe renal damage or death,
could be mistakenly attributed to statin therapy due to CK
values, when the source may in fact be variable (e.g.
extreme exercise or muscle stress accompanied by dehy-
dration) [5].
In addition to insufficient internal validation of the main
test for statin-induced myopathy, the general terminology
used to describe muscle toxicities such as myopathy and
rhabdomyolysis has been inconsistently represented in the
literature. The American College of Cardiology/American
Heart Association/National Heart, Lung, and Blood Insti-
tute standardized the terminology of muscle toxicity by
defining myalgia, myositis, and rhabdomyolysis as statin-
induced myopathies. For instance: (1) myalgia is defined as
muscle symptoms, such as ache or weakness with normal
CK levels; (2) myositis is defined as muscle symptoms
with elevated CK levels; and (3) rhabdomyolysis is defined
as muscle symptoms with CK elevation (typically[10x the
upper limit normal [ULN] value) and creatinine elevation
[4]. In this paper, the term statin-induced myopathy will
encompass all three levels of muscle toxicity defined
above.
Clinical studies have reported suspected statin-induced
myopathies in 5–10% of patients [6, 7], and as high as 25%
in some observational studies [7–9]. Reported rates of
myopathy in clinical trials may underestimate the true
incidence, because most clinical trials did not use a stan-
dard definition for statin myalgia or, in some cases, patients
were screened during the run-in period to eliminate par-
ticipants with statin intolerance [9]. Researchers are cur-
rently developing a pharmacogenomics (PGx) test aimed at
diagnosing statin-induced myopathy.
We refer to the PGx test as an in vitro diagnostic device to
identify a specific patient population (e.g. responders or
patients who are susceptible to experience serious adverse
events) as part of a personalized medicine strategy aiming to
treat patients safely and effectively with a companion tar-
geted therapeutic [10]. In our context, the purpose of the PGx
test is to assist physicians in the interpretation of CK values
in patients under statin therapy who experience muscu-
loskeletal pain symptoms with low-to-moderate CK values
(5 B ULN). The PGx test would fill the unmet need of
determining, among patients having musculoskeletal pain,
those who suffer from statin-induced myopathy and are thus
at risk of developing rhabdomyolysis. The end purpose of the
PGx test is, through a negative test result, to determinewhich
patients can maintain statin therapy and avoid further CVE.
Thus, the rational for this study is to evaluate the economic
value of a hypothetical PGx test to diagnose statin-induced
myopathy in patients who are prescribed statin therapy.
2 Methods
2.1 Economic Evaluation
We developed a decision analytic Markov state model in
TreeAge Pro software (TreeAge Software, Williamstown,
MA, USA) to assess the cost-effectiveness of a hypothet-
ical PGx test to identify statin-induced myopathy in high-
risk, secondary prevention cardiovascular (CV) patients
experiencing musculoskeletal pain. The model perspective
is that of an average statin. The model uses data inputs
from previously published studies and public sources (see
Tables 1, 2, 3). The model was developed as a Markov
cohort with one single patient for each strategy using a
1-month cycle with a time horizon of 20 years. All costs
were adjusted to 2014 CAN$. The perspective of the model
is that of a public payer in Canada.
2.1.1 PGx Test
Studies suggest that the risk of statin myopathy could be
managed when the SLCO1B1 genotype is available espe-
cially for patients being prescribed a high-dose simvastatin
[11, 12]. However, with the analysis of the data from the
SEARCH genome-wide association study, Stewart [13]
concluded that there was no direct evidence for the clinical
utility of statin prescriptions guided by the SLCO1B1
genotype. In practice, physicians rely on the CK test when
diagnosing statin-induced myopathy [11]. To date, no PGx
test for statin-induced myopathy exists. However,
researchers are developing a PGx test based on blood-based
biomarkers identified in a genome-wide genotyping study,
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for statin-induced myopathy in patients with moderate or
no CK elevation (B5x ULN). The PGx test integrates both
personalized CK reference values and a lipidomic bio-
marker. Therefore, there are no PGx test performance
parameters currently published, or available. To address
this, we used the false-negative rate (FNR)1 and false-
Table 1 Model transition probability, hazard ratio (HR), relative risk (RR), and rate inputs and values used in the sensitivity analysis
Variable Base Low High Distribution Source
Probability of a MACEa,b 0.0115 0.0086 0.0144 Beta Assumption
Probability of recurrence of a MACEa,c 0.0148 0.0111 0.0184 Beta Assumption
Probability of AMIa 0.0010 0.0008 0.0013 Beta Wagner et al. [15]
Probability of death from AMI 0.0700 0.0600 0.1100 Beta Erickson et al. [14]
Probability of strokea 0.0005 0.0003 0.0006 Beta Wagner et al. [15]
Probability of death from stroke 0.1200 0.1000 0.1900 Beta Erickson et al. [14]
Probability of recurrent AMIa 0.0042 0.0031 0.0052 Beta Wagner et al. [15]
Probability of stroke after AMIa 0.0012 0.0009 0.0015 Beta Wagner et al. [15]
Probability of recurrent strokea 0.0070 0.0053 0.0088 Beta Wagner et al. [15]
Probability of AMI after strokea 0.0016 0.0012 0.0020 Beta Wagner et al. [15]
HR of death after AMI 1.4000 1.0500 1.7500 Normal Erickson et al. [14]
HR of death after strokea 2.3000 1.7250 2.8750 Normal Erickson et al. [14]
RR: statin reduction of major CVE 0.6600 0.4950 0.8250 Normal Pedersen et al. [16]
RR: statin reduction of CV deaths 0.5800 0.4600 0.7300 Normal Pedersen et al. [16]
Probability of myopathy symptoms 0.2500 0.2000 0.3000 Beta Assumption
Rate of rhabdomyolysis (per 10,000 person-years)d 4.64 0.46 46.4 Gamma Erickson et al. [14]
AMI acute myocardial infarction, CV cardiovascular, CVE cardiovascular event, HR hazard ratio, MACE major cardiovascular event RR relative
risk
a The low and high values are set to ±25% of the base parameter values
b The monthly probability of a MACE is calculated assuming a 5-year 50% probability
c The monthly probability of a recurrent MACE is calculated assuming a 2-year 30% probability
d The rate of rhabdomyolysis is doubled for patients with a false-negative PGx test result as the likelihood of rhabdomyolysis will be higher in
the subgroup of patients with a false-negative PGx test result
Table 2 Model costs inputs and values used in the sensitivity analysis (2014 CAN$)
Variable Base Low High Distribution Source
AMIa 11,316 8487 22,632 Gamma OCCI [29]
Strokea 15,190 11,392 30,380 Gamma OCCI [29]
Fatal AMIa 18,427 13,820 36,853 Gamma Smolderen et al. [30]
Fatal strokea 30,586 22,940 61,172 Gamma Smolderen et al. [30]
Follow-up cost
Monthly cost of managing a stroke survivorb 663 497 828 Gamma Conly et al. [31]
Monthly cost of managing a non-fatal AMI survivor 129 112 147 Gamma Conly et al. [31]
Rhabdomyolysis cost Hospitalizationb 90,475 67,856 113,093 Gamma Conly et al. [31]
Drug cost (statins)b 34 25 42 Triangular RAMQ [21]
Physician visitsb 43 21 78 Gamma RAMQ [20]
Cost of PGx test 250 0 250 N/A Assumption
AMI acute myocardial infarction, OCCI Ontario case costing initiative, PGx pharmacogenomics test, RAMQ Re´gie de l’assurance me´dicament du
Que´bec, RR relative risk
a The low and high values are set respectively to -25% and ?100% of the base parameter values
b The low and high values are set to ±25% of the base parameter values
1 The false-negative rate can be expressed as 1-sensitivity.
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positive rate (FPR)2 when reporting the model results. The
FNR is the proportion of test results in the presence of
statin-induced myopathy that would falsely indicate the
absence of statin-induced myopathy (false-negative test
result). Similarly, the FPR is the proportion of test results
in the absence of statin-induced myopathy that would fal-
sely indicate the presence of statin-induced myopathy
(false-positive test result). For the base-case scenario, we
assume that the PGx test is a perfect test; specifically, that
the PGx FNR and FPR are zero. In scenario analyses, we
investigate the complete range of possible test performance
from 0 to 100% of FNR and FPR. This includes scenarios
where the PGx text is subject to misclassification, and
assesses the impact of misclassification on the economic
evaluation of the PGx strategy.
Furthermore, we assumed that the treating physician
will not require a PGx test for patients presenting with
rhabdomyolysis. Patients who present with rhabdomyolysis
progressed to the true-positive states and discontinue their
statin therapy. We assumed that patients experiencing a
CVE will return to a statin therapy regardless of the pre-
vious PGx test results. The rationale is that high-risk,
secondary prevention CV patients will have a greater fear
of CVE recurrences than rhabdomyolysis, which has a very
low incidence rate (1 per 10,000 person-years) [6, 14]
compared to the recurrence of a major CVE (1-year
probability of 0.06 major CVE following a myocardial
infarction and 0.10 following a stroke) [15].
2.1.2 Model Structure
The model target population are high-risk, secondary pre-
vention, CV patients initiating a statin. The model com-
prised two alternative strategies, with and without a PGx
test to diagnose statin-induced myopathies. The physician
diagnosis of statin-induced myopathies, in patients with
musculoskeletal pain, will determine whether they continue
or discontinue the statin therapy. Without a PGx test, we
assumed that when patients experience musculoskeletal
pain, their physician permanently interrupts the statin
therapy for fear of the patient developing rhabdomyolysis.
With a PGx test, only patients experiencing muscu-
loskeletal pain are being tested; thus, public payers only
incur the PGx test cost for these patients. We assume that
patients and physicians are fully compliant to the PGx test
results. That is, physicians will recommend either contin-
uing or permanently discontinuing the statin therapy based
on the PGx test results and patients will fully adhere to
their physician recommendations. Patients who do not
experience any musculoskeletal pain are maintained on
statin with perfect adherence.
Figure 1 shows the Markov state model structure. The
model has one initial statin state; one transitory state,
musculoskeletal pain (MSP); two discontinue-statin states
(true- and false-positive); two remain-on-statin states (true-
and false-negative); four CV states (post-AMI, post-stroke,
‘‘post-AMI and stroke’’, and death from CV); and back-
ground death. Background death can occur from any states
including the CV states whereas CV event death can only
occur from any of the CV states.
Patients enter the model upon initiating a statin in sec-
ondary prevention. Patients may have a CVE, in which
case they may transition to one the three CV states, or
remain in the statin state. Patients who experienced both
stroke and AMI, progress to the ‘‘post-AMI and -stroke’’
state. Only patients experiencing musculoskeletal pain go
through the screening process, which is represented by the
transitory state MSP. In MSP, patients are redirected to
discontinue-statin states for true- and false-positive or
remain-on-statin states for true- and false-negative states.
Essentially, these four paths differ in terms of treatment
(discontinue or remain on the statin therapy) and whether
Table 3 Model health utility inputs and values used in the sensitivity analysis
Variable Base Low High Distribution Source
Asymptomatic elderlya 0.8441 0.8394 0.8494 Beta van Kempen et al. [23]
Post-AMI eventa 0.6477 0.6383 0.6677 Beta van Kempen et al. [23]
Post-stroke eventa 0.6477 0.6383 0.6677 Beta van Kempen et al. [23]
Disutility due to AMIb 0.1270 0.0953 0.1588 Beta van Kempen et al. [23]
Disutility due to stroke eventb 0.1390 0.1043 0.1738 Beta Wagner et al. [15]
Expected disutility of myopathyb 0.0829 0.0622 0.1036 Beta Hauber et al. [22]
Expected disutility of rhabdomyolysisb 0.1390 0.1043 0.1738 Beta Assumption—disutility of stroke
AMI acute myocardial infarction
a The heath-utilities are weighted values of gender specific using the proportion of male aged 55 and older from Pedersen et al. [16]
b The low and high values are set to ±25% of the base parameter values
2 The false-positive rate can be expressed as 1-specificity.
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the musculoskeletal pain is a result of statin-induced
myopathy. With the PGx strategy, patients will be redi-
rected to these four paths based on the assumed test
parameters. Under a perfect PGx test, patients will either
move to the true-positive, discontinue-statin for patients
with statin-induced myopathy, and all other patients will
progress to the true-negative, remain-on-statin states.
Without a PGx strategy, patients will progress to discon-
tinue-statin states; when patients have statin-induced
myopathy they progress to the true-positive, discontinue-
statin state; all others progress to the false-positive, dis-
continue-statin state.
2.1.3 Transition Probabilities, Hazard Ratio, Relative Risk
and Rates
Table 1 presents the monthly transition probabilities, haz-
ard ratio, relative risk, and rates for the base-case scenario;
the values used in the deterministic, and probabilistic
sensitivity analyses, and the assumed distribution used in
the probabilistic sensitivity analysis. The model values
were varied with a ±25% for low and high values when the
deterministic sensitivity analyses boundaries were not
provided in the literature.
We assume that the 5-year major CVE probability is
50% and that major CV recurrent events have a 2-year
probability of 30%. Statins protection is captured with the
relative risk reduction from major CVE in Pedersen et al.
[16].
The model mortality is derived from the digitized
overall survival (OS) reported in the Scandinavian Sim-
vastatin Survival Study (4S), Pedersen et al. [16]; using the
DigitizeIt software (DigitizeIt, Germany), and Statistics
Canada published life tables [17]. The 4S OS curve is
applied to patients treated with a statin, whereas the pla-
cebo OS is applied to patients who discontinued statin
therapy. The monthly and annual probabilities of deaths
following a stroke or an AMI were assumed to be equal.
Indeed, a study from Law et al. [18] showed that 85% of
patients dying within the first year following an AMI, died
either before hospital admission or during the hospital
admission.
A Gamma function was used to simulate the timing of
musculoskeletal pain. The function was calibrated to
achieve a 3-year musculoskeletal pain probability of 40%.
The whole curve was moved by ±25% in the deterministic
sensitivity analysis. We assumed that 25% of patients
presenting with musculoskeletal pain had statin-induced
myopathy.
2.1.4 Costs
The Canadian cost data presented in Table 2 were obtained




















Fig. 1 Representation of the Markov state model. Patients enter the
model initiating a statin in secondary prevention. AMI acute
myocardial infarction, CV cardiovascular, CVE cardiovascular event,
FN false-negative, FP false-positive, MSP musculoskeletal pain, TN
true negative, TP true positive
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studies, and governmental public sources. The cost data
were inflated to 2014 CAN$ using the all-components
consumer price index table from Statistics Canada [19].
The low and high scenarios are set, respectively, to 75 and
200% to account for the skewness observed in health-care
costs’ data. For physician visits, the low and high values
are based on the minimal and maximal values for a
physician visit from the RAMQ physician’s code book
[20]. The statin cost is based on the average cost of a
30-day statin prescription list price in Que´bec, with ±25%
for the high and low values [21].
2.1.5 Health Utilities
Table 3 presents the health state utility values used in the
model for the base case, the deterministic sensitivity
analysis, and the distribution used in the probabilistic
sensitivity analysis. For asymptomatic elderly, post-AMI
events, post-stroke events, and expected disutility for
myopathy, the health-utility values used in the model are
converted to monthly utility values. However, for CVE
disutility of major events (i.e. AMI, stroke, and rhab-
domyolysis) we assumed that the total disutility is incurred
within the cycle where the event occurs in the model. We
assumed that the disutility value of myopathy is similar to
that of going from mild to moderate fibromyalgia [22]. For
rhabdomyolysis, we assumed that the disutility is equiva-
lent to that of a stroke. The deterministic sensitivity anal-
ysis low and high values for asymptomatic elderly, post-
AMI, and post-stroke patients are based on data from van
Kempen et al. [23], whereas the values for disutilities are
set to ±25%.
2.2 Base-Case Analysis
In the base-case analysis with a PGx test, we assume a
‘‘perfect world’’ which is defined as: (1) the PGx test is
perfect (FNR = 0% and FPR = 0%); (2) physicians will
require PGx tests for all high-risk secondary prevention CV
patients on statin therapy presenting with musculoskeletal
pain, and will recommend to either continue or interrupt
statins based on the PGx test results; and (3) patients will
adhere to their physician recommendations regardless of
whether or not they still suffer musculoskeletal pain.
For the strategy without a PGx test, we assume that
physicians, and patients, are risk-averse in the presence of
musculoskeletal pain, and interrupt the statin therapy in fear
of rhabdomyolysis. This situation is equivalent to that of a
PGx test with FNR = 0% and FPR = 100%. This would
also be the case when patients ignore physicians’ recom-
mendations to try alternative statin treatment patterns (e.g.
switch molecules, dose reduction, stop and re-challenge,
etc.).
2.3 Sensitivity Analysis
We carried out sensitivity analyses to assess the model
parameters uncertainty. Deterministic sensitivity analysis
and probabilistic sensitivity analysis parameter values are
specified in Tables 1, 2, and 3. The results of the determin-
istic sensitivity analysis are presented in a tornado diagram
while probabilistic sensitivity analysis results are summa-
rized in a cost-effectiveness acceptability curve (CEAC).
2.4 Scenario Analysis
In scenario analyses,weallow theFNRandFPRparameters to
vary from 0 to 100%, therefore allowing the analysis of the
model sensitivity to the full extent of PGx test parameter
values. The purpose of this analysis is to determine the eco-
nomically acceptable range of PGx test parameter combina-
tions. The scenario analysis is an important aspect of the
economic evaluation for three reasons. First, the model eval-
uates a hypothetical situation, thus we do not know the ‘‘real-
life’’ test parameters. Second, evaluating the complete range
of test parameters provides comprehensive picture for public
payers. Third, if the economic evaluation is done sufficiently
early, it allows test developers to understand the optimal
combination of test parameters fromaneconomicperspective.
3 Results
3.1 Base-Case Analysis
The base-case results are presented in Table 4. The results
indicate that the ‘‘with PGx test’’ strategy dominates
‘‘without PGx test’’ strategy when the PGx test costs less
than CAN$250. In fact, the ‘‘with PGx’’ test strategy
remains the dominant strategy as long as the PGx test costs
less than CAN$356, where the strategy is cost neutral. At a
willingness to pay (WTP) of CAN$1000, our results show
that the ‘‘with PGx’’ strategy would be cost effective as
long as the test costs less than CAN$906.
3.2 Sensitivity Analyses
In order to assess the robustness of the model base incre-
mental cost-effectiveness ratio (ICER) of -CAN$194, we
performed deterministic sensitivity analyses (Fig. 2). The
three most important factors are the CVE risk reduction
from statins, the cost of AMI, and the cost of statins. The
range of ICERs obtained varies from -CAN$2835 to
CAN$4321 per QALY. The maximal ICER value in the
deterministic sensitivity analysis (CAN$4321 per QALY)
is obtained with the high parameter value of the CV rela-
tive risk-reduction of 0.825, which was set to ±0.25%. The
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maximal ICER obtained is well below all accepted WTP
thresholds.
Figure 3 shows the CEAC comparing the two strategies.
We ran 10,000 simulations for the probabilistic sensitivity
analysis. The probabilistic sensitivity analysis model sim-
ulations favor the ‘‘without PGx test’’ when the payer’s
WTP is below CAN$750 per QALY. With a WTP of
CAN$0 per QALY, the model shows that the ‘‘with PGx
test’’ strategy is favored by 43% of the model simulations.
When the payer’s WTP exceeds CAN$750 per QALY,
over 50% of the model simulations favor the ‘‘with PGx
test’’ strategy and this number reaches 90% when the
payer’s WTP = CAN$6,150 per QALY.
3.3 Scenario Analyses
Because of the uncertain sensitivity of a future PGx test for
statin-inducedmyopathy, we investigated thewhole range of
possible values of FNR and FPR. Figure 4 shows the matrix
of results for the scenario analyses. The top left corner
corresponds to the ‘‘perfect test’’ (FNR = FPR = 0%), and
the bottom right corner represents the ‘‘worst test’’
(FNR = FPR = 100%). The combination of FNR and FPR
parameter values where the ‘‘with PGx test’’ dominates is
represented the by the light grey region (FNR = 80% and
FPR = 0%) and (FNR = 0% and FPR = 20%). Thus, we
can argue that a PGx would be a dominant strategy for all
practical purpose as for a diagnostic test to be considered a
valid tool would require minimal misclassification (i.e. FNR
and FPR below 20%).
The results in Fig. 4 show that even for a PGx test thatwould
totally misclassify patients (i.e. FNR = FPR = 100%), the
ICER is very low, CAN$5987 per QALY. To understand
this result, we need to consider the PGx test performance
compared to the hypothesized alternative. First, in the
‘‘without PGx test’’, every patient presentingwithMSPwill
interrupt the statin therapy; hence, patients without statin-
inducedmyopathywill bemisclassified (i.e. false-positive).
However, with the worst test possible, both patients with
and without statin-induced myopathy are misclassified (i.e.
Table 4 Results with a perfect test (i.e. FNR = 0% and FPR = 0%)
PGx test cost With PGx test Without PGx test D Costs D QALY ICER
Cost QALY Cost QALY
CAN$0 CAN$41,349 7.18 CAN$41,501 6.95 -CAN$152 0.23 -CAN$648.38
CAN$250 CAN$41,456 7.18 CAN$41,501 6.95 -CAN$45 0.23 -CAN$193.64
CAN$906 CAN$41,735 7.18 CAN$41,501 6.95 CAN$234 0.23 CAN$1000.00




Unit cost of a PGx_Test
Increased risk of death aer an AMI
Increased risk of death aer a Stroke
Reducon in risk for CV death from stans
Stan overall survival curve
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Cost of a fatal stroke
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Placebo overall survival curve
Cost of post stroke follow-up
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Cost of AMI Event
Reducon in risk  of a major CVE from stans
ICER ($ per QALY)
Base model ICER: -$193.64Fig. 2 Tornado diagram
comparing the strategy ‘‘with
PGx test’’ to ‘‘without PGx
test’’. The diagram shows 15
scenario variations. The most
important factors are the risk
reduction of CVE from statin,
followed by the cost of AMI
events, and the cost of statins.
Although the unit cost of the
PGx test, the sensitivity, and the
specificity appear in the figure,
their ranks are, respectively, 14,
15, and 23 among all parameters
varied. AMI acute myocardial
infarction, CV cardiovascular,
CVE cardiovascular event, PGx
pharmacogenomics
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false-negative and false-positive). Therefore, the differ-
ence between the two scenarios are the patients with statin-
induced myopathy. In the ‘‘without PGx test’’, these
patients are properly classified, the statin therapy is inter-
rupted, but they are at greater risk of aCVE.However, in the
‘‘with PGx test’’, these patients are misclassified as not
having statin-induced myopathy; henceforth, the statin
therapy is maintained regardless of whether patients still
experience MSP. Although, patients’ quality-of-life is
penalized with myopathy-associated disutility, these
patients benefit from the prevention of future CVE, which
counterbalances the misclassification. For these reasons,
the ICER of a PGx test that would totally misclassify
patients does not increase to an extreme value.
To assess the impact of FPR and FPR on the maximal
value of a PGx test, we have analyzed the change in the
maximal price value of the PGx test when the payer’s WTP






























the management of statin-
induced myopathy with and
without a PGx test. The curves
show the percentage of
simulations that favor one
strategy over the other. The
curves crossover when payer’s
WTP is CAN$750 per QALY.
When the payer’s WTP reaches
CAN$6150 per QALY, 90% of
the model simulations favor the
strategy ‘‘with PGx test’’. PGx
pharmacogenomics, QALY
quality-adjusted life year, WTP
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0% -$194 -$143 -$80 $1 $110 $261 $488 $867 $1,625 $3,899 Undefined
10% -$170 -$117 -$52 $32 $143 $298 $528 $906 $1,641 $3,696 $41,721
20% -$147 -$92 -$25 $62 $176 $333 $566 $942 $1,655 $3,530 $21,819
30% -$124 -$68 $2 $91 $207 $367 $601 $975 $1,668 $3,393 $15,185
40% -$101 -$44 $28 $119 $237 $400 $635 $1,006 $1,679 $3,277 $11,867
50% -$80 -$20 $53 $146 $267 $431 $667 $1,035 $1,690 $3,178 $9,877
60% -$58 $3 $78 $172 $295 $461 $697 $1,062 $1,700 $3,093 $8,550
70% -$37 $25 $101 $198 $322 $489 $726 $1,088 $1,708 $3,018 $7,603
80% -$17 $47 $125 $222 $348 $517 $754 $1,112 $1,717 $2,952 $6,892
90% $3 $68 $147 $246 $374 $543 $780 $1,135 $1,724 $2,894 $6,339
100% $23 $89 $169 $270 $398 $569 $806 $1,157 $1,731 $2,842 $5,897
Worst test
Improvement over the no PGx situation
D
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Fig. 4 Matrix of ICER results when varying the PGx test FPR and
FNR from 0 to 100%. The perfect PGx test is located at the top left
corner of the matrix ‘‘Perfect Test’’ (FPR and FNR are 0%) while the
‘‘Worst Test’’ is located at the bottom right corner (FPR and FNR are
100%). The light shaded region shows the combination of test
parameters yielding a dominant a PGx strategy. The white cells
indicate the region where the PGx test is cost effective (i.e. ICER well
below accepted WTP threshold). The black cell indicates the assumed
strategy ‘‘without PGx test’’ and thus cannot be evaluated because
both strategies yield exactly the same QALYs. In fact, in that
situation, the ‘‘without PGx test’’ dominates because with PGx test is
systematically more expensive and yields the same level of QALY.
FNR false-negative rate, FPR false-positive rate, ICER incremental
cost-effectiveness ratio, PGx pharmacogenomics, QALY quality-
adjusted life year, WTP willingness to pay
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this analysis. The results show that 10% change in FNR
reduces the maximal PGx price by less than 1% whereas a
change in 10% of FPR reduces the maximal PGx price by
10%.
4 Discussion
SCLO1B1 genotyping has been proposed for managing the
risk of statin-induced myopathy, especially in patients
using a high-dose of simvastatin [11, 12] whereas the
purpose of the PGx test in development is to assist physi-
cians and pharmacists to diagnose statin-induced myopathy
in patients with moderate or no CK elevation (5 B ULN).
We found that the ‘‘with PGx test’’ strategy to confirm
statin-induced myopathies dominates the ‘‘without PGx
test’’ strategy in our hypothesized framework where the
test costs up to CAN$356. In scenario analyses, we found
that for a PGx test cost of CAN$250, the strategy ‘‘with
PGx test’’ dominates the ‘‘without PGx test’’ for many FNR
and FPR combinations. To our knowledge, there are no
previously published papers on the economic value of a
PGx test of statin-induced myopathy.
4.1 PGx False-Negative and False-Positive
When evaluating the economic value of a PGx test it is
important to model the PGx test parameters. In our model,
the scenario analyses show that false-negative and false-
positive PGx test results have different impacts on the
economic value of the test. To appreciate that point, we
need to understand the consequences of a PGx test mis-
classification. Patients with false-negative test results
continue their statin therapy, even though they suffer from
statin-induced myopathy. Thus, they suffer from the dis-
comfort, and sometimes danger, of muscle toxicities that
we account for with statin-induced myopathy disutility.
These patients are at risk of rhabdomyolysis, which can
lead to very severe and costly outcomes; however, rhab-
domyolysis is a very rare event. Rallidis et al. [6] reported
the rate of rhabdomyolysis of 3.2 per 100,000 person-years
but most studies report a rate of rhabdomyolysis around 10
per 100,000 person-years [14, 24]. The rate of
rhabdomyolysis development is important, because these
patients continue their statin therapy, they benefit from the
prevention of CVEs, which is less costly than a hospital-
ized rhabdomyolysis, but also much more likely to occur.
In the case of false-positive PGx test results, patients’
myopathy is not related to statin therapy, and these patients
are mistakenly interrupting their statin therapy. The con-
sequences are that these patients are no longer benefiting
from the protection of statin therapy, which leads to an
increase in CVEs with the increased costs, and reduced
QALYs, associated with these events. Thus, because of the
CVE protection associated with a false-negative test
results, it turns out that an increase in FNR has a limited
impact compared to an increase in FPR.
These patients will no longer benefit from the statin
protection of CVE. For payers, patients inadequately
interrupting their statin therapy may represent an economic
loss. As explained by Cardinal et al. [25], in preventive
health strategies, patients who interrupt their treatment
before they incur any benefit represent a resource ineffi-
ciency, which they refer to as the concept of ‘‘percent
wasted patients’’. Indeed, as can be seen in the study from
Pedersen et al. [16], the statin benefit materializes after 1.5
years of statin treatment when compared to placebo.
Furthermore, the development of an accurate PGx test
would be a useful tool for physicians and pharmacists to
help maintain patients on continuous statin therapy. Many
studies highlighted the poor adherence and persistence to
statin therapy. In a claims database, Catalan and LeLorier
[26] showed that in a cohort of patients initiating a statin
only 33% were still adherent after 1 year. Dorais et al. [27],
reported that, among 19,727 patients initiating a statin,
53.3% had discontinued treatment after 1 year. Wouters
et al. [28] explored the many reasons for statin non-ad-
herence. Their study results show that among 229 patients,
40–70% doubted the necessity and lacked the knowledge
about the statin efficacy, while 20–35% were worried about
joint and muscle side effects [28].
4.2 Strength
The model design was not limited by the lack of ‘‘real-
world’’ PGx test parameters. We developed the base-case
Table 5 Maximal price of a
PGx test when the payer’s
WTP = CAN$1000
Scenario Optional PGx price assuming
WTP = CAN$1000
D Value of PGx
price (%)
FNR = 0% and FPR = 0% (Perfect test) CAN$906
FNR = 10% and FPR = 0% CAN$900 99.37
FNR = 0% and FPR = 10% CAN$816 90.00
FNR = 10% and FPR = 10% CAN$810 89.37
FNR false-negative rate, FPR false-positive rate, PGx pharmacogenomics, WTP willingness to pay
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model with a perfect PGx test environment; however, by
including the complete range of FNR and FPR in scenario
analysis, we gave the model enough flexibility to analyze
an imperfect test environment. The concept of an imperfect
test encompasses not only test errors, but also non-adher-
ence to test results by physicians and/or patients. Indeed,
when physicians or patients do not adhere to the test
results, it is comparable to a test misclassification. Our
model assesses the impact of FNR and FPR on the eco-
nomic value of the PGx test. The model shows that FNR
and FPR may affect the economic value of the PGx test
differently. Evaluating the complete range of test parame-
ters provides essential information to payers on the optimal
test parameters.
4.3 Limitations
There is uncertainty surrounding the incidence of statin-
induced severe rhabdomyolysis and its associated disutil-
ity. An increase in the rate of severe rhabdomyolysis would
increase the value of the PGx test. The results we obtained
are not generalizable to all patients under statin therapy.
The strategy ‘‘without PGx test’’ may be seen as limiting
as we assumed that all physicians and pharmacists will
recommend discontinuing statin therapy when patients suf-
fer from musculoskeletal pain. Regardless of their physician
or pharmacist recommendation, it is likely that patients will
discontinue the drug as adherence and persistence issues
with statins which will lead to an identical outcome [26–28].
Although long-term persistence issues are not addressed in
the model, we argue that in the context of this model it is not
as limiting as it first appears. The reason is that without
myopathy, patients will be treated identically in both model
strategies. Therefore, this would have no impact on the
incremental costs or incremental QALYs
5 Conclusion
Our base-case results show that a PGx test for statin-in-
duced myopathy in a high-risk secondary prevention of
CVE population would be a dominant solution for a test
cost of CAN$356 or less. Deterministic and probabilistic
sensitivity analyses show that a PGx test for statin-induced
myopathy is a cost-effective solution for all accepted WTP
thresholds. Including the full range of possible PGx test
parameters in an economic evaluation is an important
aspect when assessing the economic value of PGx tests.
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